Open AccessToxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon
Author(s) -
Beth A. Helmink,
Christina L. Roland,
Colleen M. Kiernan,
Jennifer A. Wargo
Publication year - 2020
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-019-08183-0
Subject(s) - medicine , surgical oncology , adverse effect , perioperative , intensive care medicine , intervention (counseling) , surgery , nursing
The use of immunotherapeutic agents, specifically immune checkpoint inhibitors (ICIs) for solid malignancies, is rapidly rising, and many new agents and treatment combinations are in development. However, ICIs have a unique side-effect profile of immune-related adverse events (irAEs) compared with chemotherapeutic agents or targeted therapies.